Repligen Corp. (RGEN)
167.60
-2.01
(-1.19%)
USD |
NASDAQ |
Sep 04, 16:00
167.57
-0.03
(-0.02%)
After-Hours: 20:00
Repligen Research and Development Expense (Quarterly) : 14.42M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 14.42M |
| March 31, 2026 | 14.46M |
| December 31, 2025 | 12.18M |
| September 30, 2025 | 14.18M |
| June 30, 2025 | 13.97M |
| March 31, 2025 | 12.11M |
| December 31, 2024 | 11.51M |
| September 30, 2024 | 9.71M |
| June 30, 2024 | 10.29M |
| March 31, 2024 | 11.07M |
| December 31, 2023 | 10.20M |
| September 30, 2023 | 10.54M |
| June 30, 2023 | 9.706M |
| March 31, 2023 | 12.15M |
| December 31, 2022 | 11.11M |
| September 30, 2022 | 10.19M |
| June 30, 2022 | 10.23M |
| March 31, 2022 | 11.84M |
| December 31, 2021 | 8.688M |
| September 30, 2021 | 9.154M |
| June 30, 2021 | 8.389M |
| March 31, 2021 | 7.612M |
| December 31, 2020 | 6.669M |
| September 30, 2020 | 4.422M |
| June 30, 2020 | 4.336M |
| Date | Value |
|---|---|
| March 31, 2020 | 4.702M |
| December 31, 2019 | 5.172M |
| September 30, 2019 | 5.427M |
| June 30, 2019 | 5.231M |
| March 31, 2019 | 3.62M |
| December 31, 2018 | 3.099M |
| September 30, 2018 | 3.601M |
| June 30, 2018 | 5.78M |
| March 31, 2018 | 3.288M |
| December 31, 2017 | 3.068M |
| September 30, 2017 | 2.001M |
| June 30, 2017 | 1.86M |
| March 31, 2017 | 1.742M |
| December 31, 2016 | 2.04M |
| September 30, 2016 | 1.886M |
| June 30, 2016 | 1.89M |
| March 31, 2016 | 1.539M |
| December 31, 2015 | 1.431M |
| September 30, 2015 | 1.49M |
| June 30, 2015 | 1.252M |
| March 31, 2015 | 1.568M |
| December 31, 2014 | 1.328M |
| September 30, 2014 | 1.650M |
| June 30, 2014 | 1.430M |
| March 31, 2014 | 1.201M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| BioLife Solutions, Inc. | 2.958M |
| Anika Therapeutics, Inc. | 7.341M |
| Danaher Corp. | 412.00M |
| Liquidia Corp. | 16.88M |
| Harmony Biosciences Holdings, Inc. | 46.60M |